New FDA guidance encourages NAMs adoption, but keeps advice broad
The FDA has issued new draft guidance aimed at accelerating adoption of new approach methodologies (NAMs) as alternatives to animal testing in drug development. The guidance outlines general validation principles and encourages sponsors to incorporate NAM data into regulatory submissions.
While the document reinforces the agency’s broader push to reduce reliance on animal studies, it provides relatively high-level recommendations and leaves key questions around implementation, validation standards, and regulatory expectations unresolved.
This AgencyIQ analysis explores how the guidance fits into FDA’s evolving approach to nonclinical testing and what it means for sponsors considering NAM adoption.
Fill out the form to read the full analysis.
Required *